



Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit

A unit funded by the FFPRHC and supported by the University of Aberdeen and the Scottish Programme for Clinical Effectiveness in Reproductive Health (SPCERH) to provide guidance on evidence-based practice

FACULTY STATEMENT FROM THE CEU on

NEW PUBLICATION: WHO *Selected Practice Recommendations Update*

Missed pills: new recommendations

SUMMARY

The World Health Organisation *Selected Practice Recommendations for Contraceptive Use* (WHOSPR) was first published in 2002¹ and provides evidence-based recommendations on how to use contraception effectively. The WHOSPR was adapted for UK use by the Faculty of Family Planning and Reproductive Health Care (FFPRHC).² The UK version is available on the FFPRHC website (www.ffprhc.org).³ Extensive field experience with the first edition of the WHOSPR highlighted to the WHO the need for revised recommendations for missed combined oral contraceptive pills (COCs). The WHOSPR was updated in 2004 and revised guidance on missed pills published.⁴ This guidance is now available on the WHO website (www.who.int/reproductive-health).

The FFPRHC endorses the new recommendations from WHO on missed COCs for the following reasons:

- There is new evidence on which to base guidance.
- The WHOSPR follow a published and rigorous process for assessing the available evidence.⁴
- The recommendations were developed by an international expert panel, with UK representation [See appendix I].
- Field experience shows a need for simple, harmonised guidance.

This Statement summarises the revised WHOSPR evidence-based ‘missed pill rules’ in formats which we hope clinicians will find useful. We recognise that different individuals favour different styles for the presentation of information. Thus, both tabular and flow chart styles of summary are provided; these convey the same information but in different ways.

The FFPRHC considers that the following statements may also serve as useful *aides memoire* for the ‘missed pill rules’:

- Whenever a woman realises that she has missed pills, the essential advice is **‘just keep going’**. She should take a pill as soon as possible and then resume her usual pill-taking schedule.
- **Also**, if the missed pills are in **week three**, she should **omit the pill-free interval**.
- **Also**, a back-up method (usually condoms) or abstinence should be used for 7 days if the following numbers of pills are missed:
 - **‘Two for twenty’** (ie if two or more 20 microgram ethinylestradiol pills are missed)
 - **‘Three for thirty’** (ie if three or more 30-35 microgram ethinylestradiol pills are missed)

The *fpa* has produced a revised COC user information sheet to reflect these changes; available from April 2005.

Background

The WHO convened an Expert Working Group to review the evidence and to develop recommendations. They considered the inconsistent or incorrect use of pills to be a major reason for unintended pregnancy. The WHO asked the systematic review question, ‘*What is the effect on contraceptive effectiveness when pills are missed on different days of the cycle?*’. Overall, the evidence identified was graded as: Level I, fair, indirect. (see Table 1: Levels of evidence).

| Table 1. Levels of evidence used by the WHO ⁵ | |
|---|---|
| <i>Recommendations were based on the following levels and categories of evidence:</i> | |
| Level I: | Evidence obtained from at least one properly designed randomized controlled trial. |
| Level II-1: | Evidence obtained from well-designed controlled trials without randomisation. |
| Level II-2: | Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one centre or research group. |
| Level II-3: | Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments could also be regarded as this type of evidence. |
| Level III: | Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees. |
| Quality of evidence | |
| Each study was also given a rating of good, fair, and poor based on grading the internal validity of a study. | |
| Types of evidence | |
| Direct: | The evidence was based on data directly addressing the question. |
| Indirect: | The evidence was extrapolated from other relevant data. |

The following principles underlie the WHO Expert Working Group’s recommendations:

- It is important to take an active (hormonal) pill as soon as possible when pills have been missed.
- If pills are missed, the chance that pregnancy will occur depends not only on **how many** pills were missed, but also on **when** those pills were missed. Based on data regarding ovulation, the Expert Working Group determined that missing three or more active (hormonal) pills (two or more for 20 microgram or less ethinylestradiol pills) at any time during the cycle warrants additional precautions. The risk of pregnancy is greatest when active (hormonal) pills are missed at the beginning or at the end of the active pills, i.e. when the hormone-free interval is extended.
- The evidence for ‘missed pill’ recommendations is primarily derived from studies of women using 30–35 microgram ethinylestradiol pills. The limited evidence on 20 microgram ethinylestradiol pills suggests that there may be a higher risk of pregnancy when missing such pills than when missing 30–35 microgram ethinylestradiol pills. Accordingly, the Expert Working Group recommended a more cautious approach when missing 20 microgram or less ethinylestradiol pills.
- Field experience from the first edition of the Selected Practice Recommendations for Contraceptive Use highlighted the need for simple ‘missed pill’ recommendations.

Combined oral contraceptives (COCs) reduce gonadotrophins thus inhibiting ovulation.⁶ Seven consecutive pills are sufficient to inhibit ovulation. The remaining COCs in a pack maintain anovulation in the vast majority of cycles. The COC also has effects on cervical mucus and the endometrium, which contribute to its contraceptive efficacy. Seven consecutive pills are regularly missed in the pill-free interval without losing contraceptive protection. Follicular activity is evident in the pill-free interval but ovulation does not occur.^{6,7,8,9} Extending the pill-free interval may reduce efficacy but there is wide inter-individual variation.⁸

When pills are missed, the inhibitory effects may be lifted sufficiently for ovulation to occur. Thus, intercourse following missed pills may result in pregnancy.^{10,11} Studies have suggested that missed pills are much more common than reported.^{12,13} In a study using electronic monitoring of pill-taking, up to 88% of women missed pills

on two or more consecutive days and up to 51% of women missed at least three pills per cycle, apparently without jeopardising effectiveness.¹²

The WHO Expert Group and others have identified a number of key unresolved issues:

- How do the number and timing of missed COCs affect the risk of pregnancy, and are there substantial variations among individuals or populations?
- How well do practitioners and COC-users understand and follow pill-taking instructions, including use of back-up contraception after missed pills?
- Would shortening the hormone-free interval significantly decrease pregnancy rates?
- Are regimens for missed 30–35 microgram ethinylestradiol COCs appropriate for COCs with lower doses of estrogen, especially with regard to the need for back-up protection?
- How accurately do ultrasound findings, hormonal measurements and evaluation of cervical mucus predict the risk of pregnancy during COC use?
- What are the most effective counselling and other communication strategies for maximising consistent, correct and continued use of COCs?

This Faculty Statement relates to 21-day pill regimens, and ‘missed pills’ refers to active, hormone-containing pills. Everyday regimens, which include seven inactive placebo pills, are less often used in UK practice. For women using everyday regimens, the ‘missed pill rules’ must be modified accordingly.

In applying the ‘missed pill rules’, clinicians must remember that there comes a point when a woman has missed so many pills that she must be viewed as having **stopped** taking the pill. The FFPRHC considers that if a woman has missed more than seven consecutive pills, then she has stopped using COC, and the ‘missed pill rules’ cannot be applied.

Tables 2 and 3 summarise the recommendations from the revised WHOSPR for 30-35 microgram and 20 microgram pills respectively. The advice for both 30-35 microgram and 20 microgram pills is also summarised in a flowchart, Figure 1. Clinicians may use **either** the tables or the flowchart to aid discussions with women, according to individual preference.

Table 2: Advice for women missing COCs containing 30 – 35 micrograms of ethinylestradiol

Missed ONE or TWO pills

- She should take a pill as soon as possible and then continue taking pills daily, one each day.*
- She does not need any additional contraceptive protection.

Missed THREE or more pills

- She should take a pill as soon as possible and then continue taking pills daily, one each day.*
- She should also use condoms or abstain from sex until she has taken pills for 7 days in a row.
- If she missed the pills in the third week, she should finish the pills in her current pack and start a new pack the next day. She should not have a pill-free interval. If the pill-free interval is avoided in this way, she does not need to use emergency contraception.
- If she missed the pills in the first week (effectively extending the pill-free interval) and had unprotected sex (in week 1 or in the pill-free interval), she may wish to consider the use of emergency contraception.

** If a woman misses more than one pill, she can take the first missed pill and then either continue taking the rest of the missed pills or discard them to stay on schedule.*

**Depending on when she remembers that she missed a pill(s), she may take two pills on the same day (one at the moment of remembering, and the other at the regular time, or even at the same time).*

For Everyday pill regimens

- *If a woman misses any inactive pills, she should discard the missed inactive pills and then continue taking pills daily, one each day.*

Table 3: Advice for women missing COCs containing 20 micrograms or less of ethinylestradiol

Missed ONE pill

- She should take a pill as soon as possible and then continue taking pills daily, one each day.*
- She does not need any additional contraceptive protection

Missed TWO or more pills

- She should take a pill as soon as possible and then continue taking pills daily, one each day.*
- She should also use condoms or abstain from sex until she has taken pills for 7 days in a row.
- If she missed the pills in the third week, she should finish the pills in her current pack and start a new pack the next day. She should not have a pill-free interval. If the pill-free interval is avoided in this way, she does not need to use emergency contraception.
- If she missed the pills in the first week (effectively extending the pill-free interval) and had unprotected sex (in week 1 or in the pill-free interval), she may wish to consider the use of emergency contraception.


** If a woman misses more than one pill, she can take the first missed pill and then either continue taking the rest of the missed pills or discard them to stay on schedule.*

**Depending on when she remembers that she missed a pill(s), she may take two pills on the same day (one at the moment of remembering, and the other at the regular time, or even at the same time).*

For Everyday pill regimens

- *If a woman misses any inactive pills, she should discard the missed inactive pills and then continue taking pills daily, one each day.*

Figure 1. *Advice for women missing combined oral contraceptives
(30-35 microgram and 20 microgram ethinylestradiol formulations)*



*Depending on when she remembers her missed pill she may take two pills on the same day (one at the moment of remembering and the other at the regular time) or even at the same time.

References

1. World Health Organization. *Selected Practice Recommendations for Contraceptive Use*. Geneva: 2002.
2. Glasier A, Brechin S, Raine R, Penney G. A consensus process to adapt the World Health Organization Selected Practice Recommendations for UK use. *Contraception* 2003;68:327-33.
3. Faculty of Family Planning and Reproductive Health Care. UK Selected Practice Recommendations for Contraceptive Use. <http://www.ffprhc.org.uk>. 2002.
4. World Health Organisation. Selected Practice Recommendations for Contraceptive Use [update] http://www.who.int/reproductive-health/publications/spr_2/index.html. 2004.
5. Harris RP, et al. Methods Work Group. Third US Preventive Services Task Force. Current methods of the US Preventive Services Task Force: a review of the process. *American Journal of Preventive Medicine* 2001;20 (Suppl.3):21-35.
6. Killick S.R., Eyong E, Elstein M. Ovarian follicular development in oral contraceptive cycle. *Fertility & Sterility* 1987;48:409-13.
7. Smith SK, Kirkman RJE, Arce BB, McNeilly AS, Loudon NB, Baird DT. The effect of deliberate omission of trinordiol or microgynon on the hypothalamo-pituitary-ovarian axis. *Contraception* 1986;34:513-22.
8. Killick S.R., Bancroft K, Oelbaum S, Morris J, Elstein M. Extending the duration of the pill-free interval during combined oral contraception. *Advances in Contraception* 1990;6:33-40.
9. Killick S.R. Ovarian follicles during oral contraceptive cycles: their potential for ovulation. *Fertility and Sterility* 1989;52:580-2.
10. Rosenberg MJ, Waugh MS. Causes and consequences of oral contraceptive non-compliance. *American Journal of Obstetrics and Gynecology* 1999;180:276-9.
11. Rosenberg M J, Waugh M S, Long S. Unintended pregnancies and use, misuse and discontinuation of oral contraceptives. *Journal of Reproductive Medicine* 1995;40:355-60.
12. Potter L, Oakley D, de Leon-Wong E, Canamar R. Measuring Compliance Among Oral Contraceptive Users. *Family Planning Perspectives* 1996;28:154-8.
13. Aubeny E, Buhler M, Colau JC, Vicaut E, Zadikian M, Childs M. Oral contraception: patterns of non-compliance. The Coralliance study. *The European Journal of Contraception and Reproductive Health Care* 2002;7:155-61.

References included in the systematic review of the updated WHOSPR Chapter 17

Chowdhury V et al. "Escape" ovulation in women due to the missing of low-dose combination oral contraceptive pills. *Contraception*, 1980, 22:241-247.

Creinin MD et al. The effect of extending the pill-free interval on follicular activity: triphasic norgestimate/35 micro g ethinylestradiol versus monophasic levonorgestrel/20 micro g ethinylestradiol. *Contraception*, 2002, 66:147-152.

Elomaa K, Lahteenmaki P. Ovulatory potential of preovulatory sized follicles during oral contraceptive treatment. *Contraception*, 1999, 60:275-279.

Elomaa K et al. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation. *American Journal of Obstetrics and Gynecology*, 1998, 179:41-46.

Hamilton CJ, Hoogland HJ. Longitudinal ultrasonographic study of the ovarian suppressive activity of a low-dose triphasic oral contraceptive during correct and incorrect pill intake. *American Journal of Obstetrics and Gynecology*, 1989, 161:1159-1162.

Hedon B et al. Ovarian consequences of the transient interruption of combined oral contraceptives. *International Journal of Fertility*, 1992, 37:270-276.

Killick SR. Ovarian follicles during oral contraceptive cycles: their potential for ovulation. *Fertility and Sterility*, 1989, 52:580-582.

Killick SR et al. Extending the duration of the pill-free interval during combined oral contraception. *Advances in Contraception*, 1990, 6:33-40.

Landgren BM, Csemiczky G. The effect of follicular growth and luteal function of "missing the pill." A comparison between a monophasic and a triphasic combined oral contraceptive. *Contraception*, 1991, 43:149-159.

Landgren BM, Diczfalusy E. Hormonal consequences of missing the pill during the first two days of three consecutive artificial cycles. *Contraception*, 1984, 29:437-446.

Letterie GS. A regimen of oral contraceptives restricted to the periovulatory period may permit folliculogenesis but inhibit ovulation. *Contraception*, 1998, 57:39-44.

Letterie GS, Chow GE. Effect of "missed" pills on oral contraceptive effectiveness. *Obstetrics and Gynecology*, 1992, 79:979-982.

Molloy BG et al. "Missed pill" conception: fact or fiction? *British Medical Journal (Clinical Research Edition)*, 1985, 290:1474-1475.

Morris SE et al. Studies on low dose oral contraceptives: plasma hormone changes in relation to deliberate pill ('Microgynon 30') omission. *Contraception*, 1979, 20:61-69.

Nuttall ID et al. The effect of ethinylestradiol 20 mcg and levonorgestrel 250 mcg on the pituitary-ovarian function during normal tablet-taking and when tablets are missed. *Contraception*, 1982, 26:121-135.

Spona J et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. *Contraception*, 1996, 54:71-77.

Sullivan H et al. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinylestradiol (15 microg) on ovarian activity. *Fertility and Sterility*, 1999, 72:115-120.

Tayob Y et al. Ultrasound appearance of the ovaries during the pill-free interval. *British Journal of Family Planning*, 1990, 16:94-96.

van der Spuy ZM et al. Gonadotropin and estradiol secretion during the week of placebo therapy in oral contraceptive pill users. *Contraception*, 1990, 42:597-609.

van Heusden AM, Fauser BC. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives. *Contraception*, 1999, 59:237-243.

Wang E et al. Hormonal consequences of "missing the pill." *Contraception*, 1982, 26:545-566.

Wilcox AJ, Dunson D, Baird DD. The timing of the "fertile window" in the menstrual cycle: day specific estimates from a prospective study. *British Medical Journal*, 2000, 321:1259-1262.

Wilcox AJ et al. Likelihood of conception with a single act of intercourse: providing benchmark rates for assessment of post-coital contraceptives. *Contraception*, 2001, 63:211-215.

Appendix 1: WHO International Expert Panel

Dr Yasmin H. Ahmed
Bangladesh

Dr Halida Akhter
Bangladesh

Dr Marcos Arevalo
Institute for Reproductive Health
United States of America

Dr Tsungai Chipato
Zimbabwe

Dr Maria del Carmen Cravioto
Mexico

Dr Soledad Diaz
Chile

Professor John Guillebaud
United Kingdom

Dr Kerstin Hagenfeldt
Sweden

Dr Ezzeldin Othman Hassan
Egypt

Dr Robert Hatcher
United States of America

Dr Mihai Horga
Romania

Dr Douglas Huber
Management Sciences for Health
United States of America

Dr Roy Jacobstein
Engender Health
United States of America

Dr Pisake Lumbiganon
Thailand

Dr Pamela Lynam
JHPIEGO - Johns Hopkins University
Kenya

Dr Trent MacKay
National Institute for Health
United States of America

Dr Polly Marchbanks
Centers for Disease Control and
Prevention
United States of America

Dr Olav Meirik
Chile

Dr Noel McIntosh
United States of America

Professor Helen Rees
South Africa

Dr Roberto Rivera
Family Health International
United States of America

Dr Fred Sai
Ghana

Dr Pramilla Senanayake
Sri Lanka

Dr James Shelton
USAID
United States of America

Mr Irving Sivin
The Population Council
United States of America

Dr Connie Smith
United Kingdom

Dr Fatiha Terki
International Planned Parenthood
Federation
United Kingdom

Dr Marcel Vekemans
IntraHealth International Inc.
United States of America

Dr Edith Weisberg
Australia

Dr Dawn S. Chin-Quee
Family Health International
United States of America

Dr Camaryn Chrisman
United States of America

Ms Anshu Mohllajee
CDC
United States of America

Dr Kavita Nanda
Family Health International
United States of America

Dr Linda S. Potter
United States of America

Ms Ruwaida M. Salem
United States of America

WHO

Ms Kathryn Church

Dr MaryLyn Gaffield

Dr Carlos Huezo

Ms Sarah Johnson

Mrs Gloria Lamptey

Dr Herbert Peterson

Dr Paul Van Look

Dr Helena von Hertzen

Dr Erica Marsh